EP4171233A4 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis - Google Patents

Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis Download PDF

Info

Publication number
EP4171233A4
EP4171233A4 EP21833175.9A EP21833175A EP4171233A4 EP 4171233 A4 EP4171233 A4 EP 4171233A4 EP 21833175 A EP21833175 A EP 21833175A EP 4171233 A4 EP4171233 A4 EP 4171233A4
Authority
EP
European Patent Office
Prior art keywords
trimethoxyphenyl
piperazin
carboxylate
synthesis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21833175.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4171233A1 (en
Inventor
Neil Buckley
Dan BELMONT
Sarah Bethune
Krista DIAZ
Bryan HAUSER
Myoung Goo Kim
Kumar Kannan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of EP4171233A1 publication Critical patent/EP4171233A1/en
Publication of EP4171233A4 publication Critical patent/EP4171233A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP21833175.9A 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis Pending EP4171233A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046123P 2020-06-30 2020-06-30
US202063046120P 2020-06-30 2020-06-30
PCT/US2021/039305 WO2022005928A1 (en) 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis

Publications (2)

Publication Number Publication Date
EP4171233A1 EP4171233A1 (en) 2023-05-03
EP4171233A4 true EP4171233A4 (en) 2024-08-21

Family

ID=79314883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21833175.9A Pending EP4171233A4 (en) 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis

Country Status (8)

Country Link
EP (1) EP4171233A4 (https=)
JP (2) JP7792920B2 (https=)
KR (1) KR20230031320A (https=)
CN (1) CN116056711B (https=)
AU (1) AU2021299266A1 (https=)
CA (1) CA3188286A1 (https=)
IL (1) IL299547A (https=)
WO (1) WO2022005928A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235297A1 (en) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Compounds and methods for increasing efficiency of cardiac metabolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation
WO2020243119A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) * 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102850296B (zh) * 2012-09-29 2015-01-07 瑞阳制药有限公司 曲美他嗪的制备方法
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation
WO2020243119A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022005928A1 *

Also Published As

Publication number Publication date
JP2026027462A (ja) 2026-02-18
JP2023532330A (ja) 2023-07-27
WO2022005928A1 (en) 2022-01-06
AU2021299266A1 (en) 2023-02-02
JP7792920B2 (ja) 2025-12-26
IL299547A (en) 2023-02-01
CN116056711B (zh) 2026-03-31
EP4171233A1 (en) 2023-05-03
CN116056711A (zh) 2023-05-02
KR20230031320A (ko) 2023-03-07
CA3188286A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
DE602007010894D1 (de) Tellungsverfahren dafür
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
CY1109409T1 (el) Κρυσταλλοι παραγωγου υδροξυνορεφεδρινης
RU2006135111A (ru) Производные тиазола
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
HRP20161751T1 (hr) Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
HUP0204232A3 (en) A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process for its preparation and pharmaceutical compositions containing it
DK1435915T3 (da) Orale doseringsformer til propiverin eller farmaceutisk acceptable salte deraf med en forsinket afgivelse af en aktiv bestanddel
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
EP2161265A3 (en) Compounds having selective inhibiting effect at GSK3
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
EP4171233A4 (en) Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis
EP1730113A4 (en) PROCESS FOR SYNTHESIS OF A CXCR4 ANTAGONIST
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
RU2000124676A (ru) Производные 2-арилэтил-(пиперидин-4-илметил)-амина в качестве антагонистов мускаринового рецептора
NO20005385D0 (no) Orale legemiddelpreparater med reproduserbar virkestoffrigivning av gatifloxacin eller dens farmasøytisk anvendelige salter eller hydrater
KR20160079123A (ko) 신경변성 질병을 치료하기 위한 신규한 방법
NO20052229L (no) Basiske estere av fettalkoholer og deres anvendelse som antiinfammatoriske eller immunstimulerende midler
RU2003127392A (ru) Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
CY1112218T1 (el) Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν
CO5560566A2 (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
EP1711477A4 (en) NEW CRYSTALLINE FORMS OF INHIBITOR OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1
RU2004117548A (ru) Амиды антраниловой кислоты и их применение в фармацевтике

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240717

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 213/80 20060101ALI20240712BHEP

Ipc: A61K 39/395 20060101ALI20240712BHEP

Ipc: A61K 31/675 20060101ALI20240712BHEP

Ipc: A01N 43/04 20060101AFI20240712BHEP